Spaces:
Sleeping
Sleeping
| Cluster,market,Value_MS_Change,Value_Growth,Volume_MS_Change,Volume_Growth,ASP_Growth,region | |
| Endo NA,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,NA | |
| FE NA,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,NA | |
| EUROPE,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EU5,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,EU | |
| Mid-EU,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EUROPE,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EU5,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,EU | |
| Mid-EU,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EUROPE,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EU5,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,EU | |
| Mid-EU,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EUROPE,Antihypertensive Combo Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EU5,Antihypertensive Combo Market,1.5,0.03,1.5,0.03,0.03,EU | |
| Mid-EU,Antihypertensive Combo Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EUROPE,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EU5,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,EU | |
| Mid-EU,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EUROPE,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EU5,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,EU | |
| Mid-EU,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EUROPE,Anti-EGFR Market,1.5,0.03,1.5,0.03,0.03,EU | |
| EU5,Anti-EGFR Market,1.5,0.03,1.5,0.03,0.03,EU | |
| Mid-EU,Anti-EGFR Market,1.5,0.03,1.5,0.03,0.03,EU | |
| Endo Europe,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,EU | |
| NIM Europe,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,EU | |
| NIM Europe,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,EU | |
| CV Europe,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,EU | |
| THY Europe,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,EU | |
| THY Europe,Hyperthyroid Market,1.5,0.03,1.5,0.03,0.03,EU | |
| Endo LATAM,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,LATAM | |
| NIM LATAM,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,LATAM | |
| NIM LATAM,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,LATAM | |
| CV LATAM,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,LATAM | |
| THY LATAM,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,LATAM | |
| APAC Total,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| APAC Total wo IN,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| APAC MS Cluster,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| APAC HE MS Cluster,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| APAC Direct Cluster,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| APAC Direct Cluster wo IN,Antihypertensive Combo Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| APAC Direct Cluster wo IN,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| APAC Hyperthyroid Cluster,Hyperthyroid Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| APAC METi Cluster wo IN,MET Inhibitor Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| APAC Anti-EGFR Cluster,Anti-EGFR Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| Endo APAC,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| THY APAC,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| NIM APAC,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| NIM APAC,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| THY APAC,Hyperthyroid Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| CV APAC,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,APAC | |
| Endo MEAR,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,MEAR | |
| NIM MEAR,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,MEAR | |
| NIM MEAR,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,MEAR | |
| CV MEAR,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,MEAR | |
| Endo Global,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,Global | |